Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282087 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
A Phase 2 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00282087 is a Phase 2 study that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 47 participants.
The verdict
NCT00282087, a Phase 2 study, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. The goal is to prevent relapse or recurrence of their uterine leiomyosarcoma.
Interventions
- DRUG gemcitabine, docetaxel, doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282087
The ClinicalTrials.gov registry entry for NCT00282087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gemcitabine, docetaxel, doxorubicin is the first listed.
NCT00282087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282087 about?
NCT00282087 is a clinical study titled "Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma". The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. Th...
What is the current status of trial NCT00282087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2006-01. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00282087?
The interventions under investigation include: gemcitabine, docetaxel, doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00282087?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.